Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

Abstract Objectives To determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare. Methods Data from two ongoing prospective registries,...

Full description

Bibliographic Details
Main Authors: Jens Klotsche, Ariane Klein, Martina Niewerth, Paula Hoff, Daniel Windschall, Ivan Foeldvari, Johannes-Peter Haas, Gerd Horneff, Kirsten Minden
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Arthritis Research & Therapy
Subjects:
Juvenile idiopathic arthritis
Etanercept
Effectiveness
Disease flare
Window of opportunity
Inactive disease
Online Access:https://doi.org/10.1186/s13075-021-02492-0

Internet

https://doi.org/10.1186/s13075-021-02492-0

Similar Items